This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ASLAN Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Le PDG ASLAN Pharmaceuticals est Carl Alan Jason Firth, nommé en Jan2010, a un mandat de 14.5 ans. détient directement 0.62% des actions de la société, d'une valeur de $ 10.49K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.7 ans et 2.8 ans.

Informations clés

Carl Alan Jason Firth

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	14.5yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	7.7yrs
Durée moyenne du mandat des membres du conseil d'administration	2.8yrs

Mises à jour récentes de la gestion

Recent updates

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Sep 14

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Jan 11

PDG

Carl Alan Jason Firth (51 yo)

14.5yrs

Titularisation

Dr. Carl Alan Jason Morton Firth, EMBA, Ph D., serves as Chief Executive Officer of ASLAN Pharmaceuticals Limited since January 2011. Dr. Firth served as the President of ASLAN Pharmaceuticals Limited.He...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Carl Alan Jason Firth	Founder	14.5yrs	pas de données	0.62% $ 10.5k
Kiran Kumar Asarpota	COO & Head of Finance	13.7yrs	pas de données	0.020% $ 346.9
Ben Goodger	General Counsel	7.7yrs	pas de données	0.023% $ 396.1
Stephen Doyle	Chief Business Officer	6.4yrs	pas de données	0.011% $ 185.5
Alexandre Kaoukhov	Chief Medical Officer	2.3yrs	pas de données	0% $ 0
Charlie Hsu	Investor Relations Director	no data	pas de données	pas de données
Chi-Chin Wang	IR & Corporate Development Director	no data	pas de données	pas de données

7.7yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de ASLN est chevronnée et expérimentée (7.7 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Carl Alan Jason Firth	Founder	14yrs	pas de données	0.62% $ 10.5k
Robert Hoffman	Independent Non-Executive Director	5.8yrs	US$63.25k	0.027% $ 450.0
Neil Graham	Independent Director	3.4yrs	US$66.29k	0% $ 0
Lawrence F. Eichenfield	Chairman of Scientific Advisory Board	2.8yrs	pas de données	pas de données
Andrew Howden	Independent Chairman	8.3yrs	US$92.38k	0.19% $ 3.2k
Reynold A. Panettieri	Scientific Advisor	less than a year	pas de données	pas de données
Kathleen M. Metters	Independent Director	3.3yrs	US$58.50k	0% $ 0
Eric Simpson	Member of Scientific Advisory Board	2.8yrs	pas de données	pas de données
Peter Foley	Member of Scientific Advisory Board	2.8yrs	pas de données	pas de données
Melinda Jennifer Gooderham	Member of Scientific Advisory Board	2.8yrs	pas de données	pas de données
Ramaswamy Krishnan	Scientific Advisor	less than a year	pas de données	pas de données

2.8yrs

Durée moyenne de l'emploi

65.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la ASLN n'est pas considéré comme expérimenté ( 2.8 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

This company listing is no longer active

ASLAN Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

High number of new and inexperienced directors

ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director

ASLAN Pharmaceuticals Announces Executive Changes

Recent updates

ASLAN Pharmaceuticals Limited(NasdaqCM:ASLN) dropped from NASDAQ Composite Index

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

New major risk - Financial position

Aslan Pharmaceuticals to Present Additional Data from Interim Analysis of Trek-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Limited Announces New Translational Data on Eblasakimab in COPD

High number of new and inexperienced directors

New major risk - Market cap size

New minor risk - Share price stability

ASLAN Pharmaceuticals Limited Presents New Data on Eblasakimab in Atopic Dermatitis and Copd Translational Models At the 7Th Dermatology Drug Development Summit

New major risk - Negative shareholders equity

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

ASLAN Pharmaceuticals Presents New Data from Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker

New major risk - Financial position

Aslan Pharmaceuticals Limited Announces Phase 2B Treatment of Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2B Study in Atopic Dermatitis

Aslan Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Price target decreased by 8.6% to US$16.00

Aslan Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

Price target increased to US$5.50

Aslan Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking E-Posters At the 51St Annual European Society for Dermatological Research Meeting

Price target increased to US$5.50

ASLAN Pharmaceuticals Limited Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Price target decreased to US$5.50

ASLAN Pharmaceuticals Limited Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

Aslan Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation At the 2022 Society for Investigative Dermatology Annual Meeting

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

ASLAN Pharmaceuticals Limited Screens the First Patient in Its Phase 2B Dose-Ranging Clinical Study of Eblasakimab in Adults with Moderate-To-Severe Atopic Dermatitis

ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

ASLAN Pharmaceuticals Limited announced that it expects to receive SGD 45 million in funding from K2 HealthVentures

ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director

ASLAN Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of $60 million.

ASLAN Pharmaceuticals Limited announced that it expects to receive $17.999999 million in funding from Vivo Capital, LLC, Citadel Enterprise Americas LLC

ASLAN Pharmaceuticals Announces Executive Changes

ASLAN Pharmaceuticals Limited Announces New Data from a Study Conducted by University of Liverpool, UK

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Aslan Pharmaceuticals Limited Announces Clinical Development of Aslan004

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

ASLAN Pharmaceuticals Limited Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

ASLAN Pharmaceuticals Limited(GTSM:6497) dropped from S&P Global BMI Index

ASLAN Pharmaceuticals Announces Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen